S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35

ADVANZ PHARMA Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/10/2021)
Today's Range
50-Day Range
52-Week Range
Volume39 shs
Average Volume11,851 shs
Market Capitalization$834.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CXRXF News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter.



ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$525.58 million
Book Value
$0.16 per share


Net Income




Market Cap
$834.46 million
Next Earnings Date


Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

ADVANZ PHARMA (OTCMKTS:CXRXF) Frequently Asked Questions

What stocks does MarketBeat like better than ADVANZ PHARMA?

Wall Street analysts have given ADVANZ PHARMA a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADVANZ PHARMA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has ADVANZ PHARMA's stock been impacted by COVID-19 (Coronavirus)?

ADVANZ PHARMA's stock was trading at $3.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CXRXF stock has increased by 375.2% and is now trading at $17.06.
View which stocks have been most impacted by COVID-19

Who are ADVANZ PHARMA's key executives?

ADVANZ PHARMA's management team includes the following people:
  • Mr. Graeme Neville Duncan, CEO & Exec. Director (Age 46, Pay $1.26M)
  • Mr. Adeel Ahmad, CFO & Exec. Director (Age 46, Pay $752.73k)
  • Mr. Karl Ian Belk, Chief Operations Officer (Age 52, Pay $685.79k)
  • Mr. Robert Sully, Gen. Counsel (Age 47, Pay $669.75k)
  • Mr. Paul Burden, Chief Commercial Officer of Strategic Growth Unit (Age 46, Pay $638.96k)
  • Mr. Adam Peeler, VP of Investor Relations & Communications
  • Mr. Guy Clark, Chief Corp. Devel. Officer (Age 50)
  • Mr. Arijit Mookerjee, MD and CFO of CPI & CLI
  • Mr. Andrew Patrick Hoyt, Chief Financial Officer of US Bus.es
  • Mr. Robert D. Ford, MD & Sr. Director of Legal Affairs of CPI and CLI (Age 54)

What is ADVANZ PHARMA's stock symbol?

ADVANZ PHARMA trades on the OTCMKTS under the ticker symbol "CXRXF."

How do I buy shares of ADVANZ PHARMA?

Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADVANZ PHARMA's stock price today?

One share of CXRXF stock can currently be purchased for approximately $17.06.

How much money does ADVANZ PHARMA make?

ADVANZ PHARMA has a market capitalization of $834.46 million and generates $525.58 million in revenue each year.

How many employees does ADVANZ PHARMA have?

ADVANZ PHARMA employs 429 workers across the globe.

What is ADVANZ PHARMA's official website?

The official website for ADVANZ PHARMA is www.advanzpharma.com.

Where are ADVANZ PHARMA's headquarters?


How can I contact ADVANZ PHARMA?

ADVANZ PHARMA's mailing address is 85 KING WILLIAM STREET, LONDON X0, EC4N 7BL. The company can be reached via phone at 44-20-8588-9100 or via email at [email protected].

This page was last updated on 9/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.